Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis
Authors' conclusion
SGLT-2is were associated with better cardiorenal protection than GLP-1RAs and nsMRAs in patients with CKD and T2D.
Study context
- Population
- RCTs in patients with chronic kidney disease (CKD) and T2D, follow-up ≥24 weeks; searches to 25 November 202229 studies
- Comparison
- SGLT2i vs GLP-1 RA vs nsMRA
- Outcome
- MACE and composite renal outcomes (CRO)
Methodological detailsfrequentist approach, follow-up ≥24 weeks
- Frequentist approach
- Follow-up ≥24 weeks
Pooled result
As reported in the abstract
CRO
Relative risk (95% CI)P value
SGLT-2isvs GLP-1RAs
0.77(0.64–0.91)
P = 0.003SGLT-2isvs nsMRAs
0.78(0.68–0.90)
P = 0.001Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Heart failure hospitalization (HFH)SGLT-2isvs GLP-1RAsRisk reduced by 31% | 0.69 (0.55–0.88) | P = 0.002 | |
| Heart failure hospitalization (HFH)SGLT-2isvs nsMRAsRisk reduced by 22% | 0.78 (0.63–0.95) | P = 0.016 | |
| 0.512Relative risk (log scale) |
Other secondary outcomes (CV death, all-cause death, stroke, MI)
- SGLT-2is did not significantly reduce other secondary outcomes vs GLP-1RAs and non-steroidal mineralocorticoid receptor antagonists (nsMRAs)
Original publication
Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis. Diabetes Obes Metab. Published 22 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →